Autres langues Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
55,41 ^USD	-0,47 %		+0,14 %	+25,79 %

12/09	Scholar Rock reçoit l'approbation de la FDA pour l'ISEMBYLD (apitegromab-mstn) dans le traitement de l'amyotrophie spinale	CI
11/09	Scholar Rock obtient son premier feu vert de la FDA pour une maladie neuromusculaire rare	RE

Autres langues

12/09	Scholar Rock Receives FDA Approval For ISEMBYLD Apitegromab-Mstn For Treatment Of Spinal Muscular Atrophy
12/09	Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
11/09	Scholar Rock gets first FDA nod for rare muscle-wasting disease
11/09	US FDA approves Scholar Rock's muscle weakness drug
11/09	Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy
02/09	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial
02/09	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug
02/09	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
27/08	Scholar Rock to Present at Upcoming Investor Conferences
21/08	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says
21/08	Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
21/08	Scholar Rock Announces Removal Of Catalent Indiana As Fill-Finish Facility And Progresses Apitegromab Regulatory Filings With FDA, EMA, And PMDA
21/08	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
21/08	Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility
21/08	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
14/08	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date
07/08	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag
07/08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date
07/08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
07/08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag -- Update
06/08	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Scholar Rock Q2 Net Loss Narrows
06/08	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials